BeOne Medicines Ltd. 8-K

What Happened

• On April 14, 2026, BeOne Medicines Ltd. filed a Current Report on Form 8-K (Item 2.02) reporting that it submitted its 2025 Annual Report (the "STAR Annual Report") to the Science and Technology Innovation Board (“STAR Market”) of the Shanghai Stock Exchange. The STAR Annual Report covers the year ended December 31, 2025 and was prepared under China Accounting Standards for Business Enterprises (CAS) and other PRC accounting rules (collectively “PRC GAAP”). The 8-K notes that PRC GAAP differ from U.S. GAAP and attaches Exhibit 99.1 with selected U.S. GAAP-prepared financial information and a summary of material differences.

Key Details

• Filing date: April 14, 2026; Reporting Period: year ended December 31, 2025.
• The STAR Annual Report was prepared in Chinese and is publicly available only on the Shanghai Stock Exchange website (www.sse.com.cn).
• Exhibit 99.1 to the Form 8-K includes U.S. GAAP-prepared information for items such as gross profit margin ratio, research & development expenses allocated by key products and other R&D projects, production/sales/inventory units, and a summary of material differences between PRC GAAP and U.S. GAAP.
• The STAR Annual Report itself and the content on the Shanghai Stock Exchange site are not incorporated by reference into the 8-K and are not deemed filed with the U.S. SEC.

Why It Matters

• For investors, the filing signals the company has published its 2025 annual results under PRC reporting rules and provided a U.S.-GAAP comparison for key metrics. Because PRC GAAP can differ from U.S. GAAP, investors should review Exhibit 99.1 for comparable U.S.-GAAP figures (gross margin, R&D breakdown, inventory and sales units) rather than relying solely on the PRC-only report. Also note the STAR Annual Report is available only in Chinese on the Shanghai exchange site and is not treated as part of BeOne’s SEC filings.